Actinium Pharmaceuticals Inc (AMEX: ATNM) has seen a rise in its stock price by 29.53 in relation to its previous close of 1.49. However, the company has experienced a 62.18% gain in its stock price over the last five trading sessions. prnewswire.com reported 2025-03-25 that – Actinium will present 3 separate multi-billion-dollar market opportunities for Actimab-A and Iomab-ACT in myeloid malignancies, solid tumors and cell & gene therapy conditioning – Dr. Ehab Atallah, Professor of Medicine at the Medical College of Wisconsin to highlight Actimab-A clinical results, mutation agnostic mechanism and backbone therapy potential – Clinical proof of concept data from frontline AML trial under NCI CRADA, Actimab-A solid tumor program with PD-1 checkpoint inhibitors and Iomab-ACT commercial CAR-T trial together with other expected 2025 milestones to be outlined – Actinium to highlight manufacturing infrastructure development activity to support revitalized clinical programs NEW YORK, March 25, 2025 /PRNewswire/ — Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, will host an investor call at 8:00 am ET today that will feature KOL Dr. Ehab Atallah, Professor of Medicine at the Medical College of Wisconsin and principal investigator of the Actimab-A + CLAG-M combination trial in patients with relapsed/refractory acute myeloid leukemia (r/r AML). Dr. Atallah will discuss Actimab-A clinical results to date including recently published long-term survival outcomes and the planned pivotal Phase 2/3 clinical trial in r/r AML and trials to be conducted under Actinium’s cooperative research and development agreement (CRADA) with the National Cancer Institute (NCI).
Is It Worth Investing in Actinium Pharmaceuticals Inc (AMEX: ATNM) Right Now?
Company’s 36-month beta value is -0.17.Analysts have differing opinions on the stock, with 2 analysts rating it as a “buy,” 2 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for ATNM is 30.40M, and currently, short sellers hold a 7.39% ratio of that floaft. The average trading volume of ATNM on March 25, 2025 was 239.73K shares.
ATNM’s Market Performance
ATNM’s stock has seen a 62.18% increase for the week, with a 64.96% rise in the past month and a 72.32% gain in the past quarter. The volatility ratio for the week is 12.14%, and the volatility levels for the past 30 days are at 7.11% for Actinium Pharmaceuticals Inc The simple moving average for the past 20 days is 55.14% for ATNM’s stock, with a -29.14% simple moving average for the past 200 days.
Analysts’ Opinion of ATNM
Many brokerage firms have already submitted their reports for ATNM stocks, with B. Riley Securities repeating the rating for ATNM by listing it as a “Neutral.” The predicted price for ATNM in the upcoming period, according to B. Riley Securities is $2 based on the research report published on August 07, 2024 of the previous year 2024.
Stephens, on the other hand, stated in their research note that they expect to see ATNM reach a price target of $25. The rating they have provided for ATNM stocks is “Overweight” according to the report published on May 14th, 2024.
HSBC Securities gave a rating of “Buy” to ATNM, setting the target price at $11.60 in the report published on September 06th of the previous year.
ATNM Trading at 57.63% from the 50-Day Moving Average
After a stumble in the market that brought ATNM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -81.15% of loss for the given period.
Volatility was left at 7.11%, however, over the last 30 days, the volatility rate increased by 12.14%, as shares surge +80.00% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +61.72% upper at present.
During the last 5 trading sessions, ATNM rose by +73.95%, which changed the moving average for the period of 200-days by -75.70% in comparison to the 20-day moving average, which settled at $1.2510. In addition, Actinium Pharmaceuticals Inc saw 53.17% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for ATNM
Current profitability levels for the company are sitting at:
- -555.05 for the present operating margin
- -6.46 for the gross margin
The net margin for Actinium Pharmaceuticals Inc stands at -505.12. The total capital return value is set at -0.6. Equity return is now at value -100.05, with -47.84 for asset returns.
Based on Actinium Pharmaceuticals Inc (ATNM), the company’s capital structure generated 0.04 points at debt to capital in total, while cash flow to debt ratio is standing at -20.35. The debt to equity ratio resting at 0.04. The interest coverage ratio of the stock is -82.19.
Currently, EBITDA for the company is -51.13 million with net debt to EBITDA at 1.74. When we switch over and look at the enterprise to sales, we see a ratio of -246.73. The liquidity ratio also appears to be rather interesting for investors as it stands at 10.25.
Conclusion
In a nutshell, Actinium Pharmaceuticals Inc (ATNM) has experienced a better performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
